Cargando…
Casp8 acts through A20 to inhibit PD‐L1 expression: The mechanism and its implication in immunotherapy
Immunotherapy targeting the PD‐L1/PD‐1 pathway is a novel type of clinical cancer treatment, but only small subsets of patients can benefit from it because of multiple factors. PD‐L1/PD‐1 expression is a biomarker for predicting the efficacy of anti‐PD‐L1/PD‐1 therapy, which highlights the importanc...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8253292/ https://www.ncbi.nlm.nih.gov/pubmed/33934451 http://dx.doi.org/10.1111/cas.14932 |